Hikma shares drop 7% on weaker margins despite solid revenue, maintained outlook

Published 07/08/2025, 11:16
© Reuters.

Investing.com -- Hikma Pharmaceuticals (OTC:HKMPY) shares fell more than 7% on Thursday after the company reported lower first-half margins in its injectables and U.S. generics units, even as it posted higher group revenue and reaffirmed full-year guidance.

Group revenue for the first half of 2025 rose 5.7% to $1.66 billion, up from $1.57 billion a year earlier. 

Core operating profit fell 7.2% to $373 million, with the group margin narrowing to 22.5% from 25.6%.

The British pharmaceutical company kept its full-year 2025 guidance unchanged, projecting revenue growth between 4% and 6%, and core EBIT in the range of $730 million to $770 million.

Injectables, the largest segment by sales, grew 12.2% year over year to $683 million, beating consensus expectations of $658 million. 

Despite the top-line strength, core EBIT in the segment fell 8%, and the margin dropped to 30% from 36.3%. 

The company cited geographic mix, increased U.S. competition, and a dilutive effect from its recently acquired Xellia portfolio. 

Full-year injectables revenue growth guidance was reiterated at 7% to 9%, but the margin forecast was reduced to 32%–33% from “mid-30s.”

Revenue in the U.S. generics segment (US Rx) slipped 0.9% to $523 million, matching consensus estimates. Core EBIT declined 12% to $92 million, with the margin falling to 17.6% from 19.7%. 

Hikma attributed the drop to increased research and development spending, partially offset by lower sales and marketing costs. Inhalation volumes increased, and sodium oxybate maintained its market position. The company said its Columbus (WA:CLC) facility is being readied for a contract manufacturing agreement with a global pharmaceutical company.

Branded revenue rose 4.3% to $437 million, with core EBIT up 3% to $133 million and a margin of 30.4%, slightly lower than 30.8% a year earlier. 

The company cited tender timing as a key factor. Full-year branded revenue growth guidance of 6% to 7% in constant currency and a margin of approximately 25% remain unchanged.

Foreign exchange pressures affected injectables during the first half but are expected to benefit the branded business in the second half, the company said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.